BetaGlue Therapeutics
PrivateLast Round
VC Round
Dec 16, 2024
Total Funding Raised
$15.57M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
BetaGlue Therapeutics is an oncology company developing YntraDose, a radiotherapy platform designed for the localized and targeted treatment of unresectable solid tumours.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
BetaGlue Therapeutics Comparables
Compare BetaGlue Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| KORTUC INC. | 75% | |
| GT Medical Technologies | 68% | |
| OncoSil Medical Ltd | 68% |
BetaGlue Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Dec 16, 2024 | ||||
| Grant | Mar 4, 2024 | ||||
| VC Round | Jul 28, 2022 | ||||
| Series A | Sep 7, 2016 |
Key People
Founding team and executive leadership
BetaGlue Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| European Innovation Council Fund | Grant, VC Round |
| Neva SGR | VC Round |
| Fondazione ENEA Tech | VC Round |
| Innogest Capital | VC Round |
| Fin Posillipo S.p.A. | VC Round |
| Kairos Partners SGR | VC Round |
| Panakès Partners | VC Round, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 245% MoM.
- May 16, 2026
Monthly visitors grew 101% MoM, reaching 1K.
BetaGlue Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about BetaGlue Therapeutics's valuation, stock price, and market status.
Is BetaGlue Therapeutics a public or private company?
BetaGlue Therapeutics is a private company.
What is the current stock price of BetaGlue Therapeutics?
BetaGlue Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is BetaGlue Therapeutics worth (valuation)?
Valuation information for BetaGlue Therapeutics is not publicly available.
Can I buy BetaGlue Therapeutics stock?
BetaGlue Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was BetaGlue Therapeutics's last funding round?
BetaGlue Therapeutics's most recent funding round was VC Round on December 16, 2024.
Who are the main investors in BetaGlue Therapeutics?
Key investors in BetaGlue Therapeutics include Panakès Partners.
Will BetaGlue Therapeutics IPO soon?
No public IPO plans have been announced for BetaGlue Therapeutics.
How can I track BetaGlue Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor BetaGlue Therapeutics's secondary market activity and sign up for updates.